R2810-ONC-1676 : An Open-Label, Randomized, Phase 3 Clinical Trial of REGN2810 Versus Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Carcinoma

Female<br/>OnlyGender Female
Only

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

ThreePhase Three

18+Age Over 18

Female Reproductive<br/>System CancersCancer LocationFemale Reproductive
System Cancers

Systemic therapy,Treatment | Female reproductive organsCervix

Trial Overview Read MoreRead more

This phase III trial is comparing the overall survival of patients with advanced cervical cancer who receive either immunotherapy or investigator's choice of chemotherapy for the treatment of their cancer.
 

This trial is treating patients with cervical cancer.

This is a systemic therapy trial.

You may be able to join this trial if:

  • You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
  • You have had treatment, but your cancer has come back.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have been diagnosed with a prior or secondary type of cancer.
  • You have had certain treatments, surgical procedures or drugs.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

An Open-Label, Randomized, Phase 3 Clinical Trial of REGN2810 Versus Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Carcinoma

Commercial Sponsor

Regeneron Pharmaceuticals

Summary

Eligible patients will be randomised to receive Cemiplimab or the investigator's choice of chemotherapy for up to 96 weeks. The different chemotherapy options for the investigator to choose from include: (1) Antifolate: Pemetrexed, (2) Topoisomerase 1 inhibitor: Topotecan or Irinotecan, (3) Nucleoside analogue: Gemcitabine or (4) Vinca alkaloid: Vinorelbine. Following the treatment phase, patients will enter the follow up period, which will continue until death, completion of the study or withdrawal of the patient.

Recruiting Hospitals Read MoreRead more

PCCTU (Parkville Cancer Clinical Trials Unit) *
Parkville
Enquiries Line Coordinator
clinicaltrials.enquiries@petermac.org
03 8559 7456 (9am-2pm, Mon-Fri)

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next